Terms: = Sarcomas AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
187 results:
1. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
2. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
3. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
4. A phase 2 trial of zanidatamab in her2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M; Chui MH; Zhou Q; Iasonos A; Sarasohn D; Cohen S; Friedman C; Grisham R; Konner J; Kyi C; Rubinstein M; Troso-Sandoval T; Aghajanian C; Makker V
Gynecol Oncol; 2024 Mar; 182():75-81. PubMed ID: 38262242
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of Pyrotinib With/Without Trastuzumab in treatment-Refractory, her2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.
Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
[TBL] [Abstract] [Full Text] [Related]
6. The Future of her2-Targeted treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract] [Full Text] [Related]
7. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With her2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
[TBL] [Abstract] [Full Text] [Related]
9. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract] [Full Text] [Related]
10. erbb2 (her2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C; Moser LM; Kreyenberg H; Bonig HB; Tonn T; Wels WS; Gradhand E; Ullrich E; Meister MT; Koerkamp MG; Holstege FCP; Drost J; Klusmann JH; Bader P; Merker M; Rettinger E
Front Immunol; 2023; 14():1228894. PubMed ID: 37662907
[TBL] [Abstract] [Full Text] [Related]
11. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
12. Anti-her2 affibody-decorated arsenene nanosheets induce ferroptosis through depleting intracellular GSH to overcome cisplatin resistance.
He P; Xu S; Miao Z; Que Y; Chen Y; Li S; Ma Q; Yang R; Wei W; Zha Z; Hu Y
J Nanobiotechnology; 2023 Jun; 21(1):203. PubMed ID: 37370105
[TBL] [Abstract] [Full Text] [Related]
13. A network pharmacology-based investigation of brugine reveals its multi-target molecular mechanism against Breast Cancer.
Qayoom H; Alkhanani M; Almilaibary A; Alsagaby SA; Mir MA
Med Oncol; 2023 Jun; 40(7):202. PubMed ID: 37308611
[TBL] [Abstract] [Full Text] [Related]
14. Risk-adjusted benchmarking of long-term overall survival in patients with her2-positive early-stage Breast cancer: A Swedish retrospective cohort study.
Thurell J; Manouchehri N; Fredriksson I; Wilking U; Bergh J; Ryden L; Koppert LB; Karsten MM; Kiani NA; Hedayati E
Breast; 2023 Aug; 70():18-24. PubMed ID: 37295176
[TBL] [Abstract] [Full Text] [Related]
15. Clinically Aggressive Uterine Epithelioid Leiomyosarcoma with Rhabdomyoblastic Differentiation and High Proliferation Rate: A Case Report.
Kim JY; Kim B
Am J Case Rep; 2023 May; 24():e939349. PubMed ID: 37190674
[TBL] [Abstract] [Full Text] [Related]
16. Landscape of neoadjuvant therapy in her2-positive breast cancer: a systematic review and network meta-analysis.
Villacampa G; Matikas A; Oliveira M; Prat A; Pascual T; Papakonstantinou A
Eur J Cancer; 2023 Sep; 190():112885. PubMed ID: 37142539
[TBL] [Abstract] [Full Text] [Related]
17. Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for her2-targeted therapy specimen selection.
Yoshida H; Mizoguchi C; Saito A; Kitadai R; Yamamoto K; Nishikawa T; Kato T; Yonemori K
Ann Diagn Pathol; 2023 Aug; 65():152150. PubMed ID: 37119646
[TBL] [Abstract] [Full Text] [Related]
18. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa T; Hasegawa K; Matsumoto K; Mori M; Hirashima Y; Takehara K; Ariyoshi K; Kato T; Yagishita S; Hamada A; Kawasaki M; Kawashima S; Tomatsuri S; Nagasaka Y; Yoshida H; Machida R; Hirakawa A; Nakamura K; Yonemori K
J Clin Oncol; 2023 May; 41(15):2789-2799. PubMed ID: 36977309
[TBL] [Abstract] [Full Text] [Related]
19. her2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.
Zhou L; Shao Z; Liu Y; Yan X; Li J; Wu X; Tang B; Li S; Cui C; Chi Z; Si L; Kong Y; Mao L; Lian B; Wang X; Bai X; Dai J; Guo J; Sheng X
Oncologist; 2023 Aug; 28(8):e617-e624. PubMed ID: 36971495
[TBL] [Abstract] [Full Text] [Related]
20. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract] [Full Text] [Related]
[Next]
